Drugs Made In America Acquisition Corp. Units
NASDAQ Global MarketTotal Valuation
Drugs Made In America Acquisition Corp. Units carries a market capitalization of 262.14M, placing it among publicly traded companies globally.
| Market Cap | 262.14M |
| Enterprise Value | N/A |
Share Statistics
Drugs Made In America Acquisition Corp. Units currently has 24.28M shares outstanding.
| Shares Outstanding | 24.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.87 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Drugs Made In America Acquisition Corp. Units maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.02 |
| Quick Ratio | 0.01 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 6.23 |
| Return on Assets (ROA) | 15.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Drugs Made In America Acquisition Corp. Units's stock has gained approximately 7.06107% over the past 52 weeks. The 50-day moving average sits at 10.88, while the 200-day moving average is 10.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | 7.06107% |
| 50-Day Moving Average | 10.88 |
| 200-Day Moving Average | 10.72 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.63M, while operating income came in at -2.63M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.63M |
| Pretax Income | 6.09M |
| Net Income | 6.09M |
| EBITDA | -2.63M |
| EBIT | -2.63M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at 137.77M, with working capital of -2.88M providing operational flexibility.
| Cash & Cash Equivalents | 20,280.00 |
| Total Debt | N/A |
| Net Debt | 929,720.00 |
| Equity (Book Value) | 137.77M |
| Book Value Per Share | 5.67 |
| Working Capital | -2.88M |
Cash Flow
Drugs Made In America Acquisition Corp. Units produced -517,145.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -517,145.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -517,145.00 |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 38.11 |
| FCF Yield | N/A |
Scores
Drugs Made In America Acquisition Corp. Units posts an Altman Z-Score of 16.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 16.76 |